by Mark Curtis | Aug 11, 2014
. Welcome to your deal review for the month of July. There was financing activity this past month as StemCells and Fate Therapeutics each secured $20 million in funding. Bluebird bio was busy with the acquisition of a privately-held genome editing company; clearly a...
by Mark Curtis | Jul 21, 2014
. The Centre for Commercialization of Regenerative Medicine (CCRM) just finished hosting the 7th annual Business of Regenerative Medicine course here in Toronto, which saw many notable figures in the space come to weigh-in on a number of critical issues relevant to...
by Mark Curtis | Jul 9, 2014
. Welcome to your Update from the Clinic for the month of June. Neuralstem presented final data on a first-in-class drug for the treatment of major depressive disorder, which is proving to be an effective and non-invasive means to boost brain volume. OncoMed has a...
by Mark Curtis | Jun 25, 2014
. Welcome to your regenerative medicine deal review for the month of May. The space was quiet this past month; however, NeoStem did strike up a licensing deal with China-based Cellular Biomedicine Group to provide international reach to its newly acquired targeted...
by Lisa Willemse | Jun 3, 2014
> Bench to beside is a deceptively simple phrase. Only 15 characters and relatively jargon-free (assuming you know what bench and bedside are referring to), it’s rather easy to drop into documents or presentations without compromising space or time limits. And,...
by Mark Curtis | May 22, 2014
. Welcome to your Update from the Clinic for the month of April. Athersys provides disappointing interim results for its MultiStem® cell therapy in ulcerative colitis patients. Sernova continues to demonstrate safety and biocompatability of its Cell Pouch technology...
Comments